title: Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
abstract: The influence of sex on the development of obesity, Type 2 Diabetes Mellitus (T2DM), and dyslipidemia is well documented, although the molecular mechanism underlying those differences reminds elusive. Ligands of peroxisome proliferator-activated receptors (PPARs) are used as oral antidiabetics (PPARgamma agonists: thiazolidinediones, TZDs), or for the treatment of dyslipidemia and cardiovascular diseases, due to their lipid-lowering properties (PPARalpha agonists: fibrates), as PPARs control transcription of a set of genes involved in the regulation of lipid and carbohydrate metabolism. Given a high prevalence of those metabolic disorders, and thus a broad use of PPAR agonists, the present review will discuss distinct aspects of sex-specific differences in antiobesity treatment using those groups of PPAR ligands.
authors.affiliation: Charité-Universitätsmedizin Berlin, Berlin, Germany. verena.benz@charite.de
authors.forename: Verena
authors.initials: V
authors.lastname: Benz
authors.forename: Ulrich
authors.initials: U
authors.lastname: Kintscher
authors.forename: Anna
authors.initials: A
authors.lastname: Foryst-Ludwig
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D050171:Dyslipidemias / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D047493:PPAR alpha / Q000819:agonists*; D047495:PPAR gamma / Q000819:agonists* / Q000235:genetics; D011110:Polymorphism, Genetic; D012727:Sex Characteristics; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D047493:PPAR alpha; D047495:PPAR gamma; D045162:Thiazolidinediones